PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=11030152;
RX   PubMed=18083107;
RX   PubMed=19153074;
RX   PubMed=19472407;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=24135919;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25984343;
RX   PubMed=26361996;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29444439;
RX   PubMed=29681454;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31803961;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-294.html
WW   https://www.atcc.org/en/support/technical-support/faqs/normal-growth-and-morphology-of-htb-174-nci-h441-cells
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Part of: RAS genetic alteration cell panel (ATCC TCP-1031).
CC   Population: Caucasian.
CC   Doubling time: 58 hours (Note=In RPMI 1640 + 10% FBS), 138 hours (Note=In ACL-3), 99 hours (Note=In ACL-3 + BSA) (PubMed=3940644); 80 hours (PubMed=25984343); 46.5 hours (PubMed=29681454).
CC   HLA typing: A*02:01,03:01; B*38:01,44:03; C*16:02,16:02; DQB1*06:07,06:07; DRB1*13:23,14:103 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=1311061; ATCC=HTB-174; Cosmic-CLP=908460; DepMap=ACH-000638).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Homozygous (PubMed=1311061; PubMed=10536175; PubMed=20557307; Cosmic-CLP=908460; DepMap=ACH-000638).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: shRNA library screening.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.09%; Native American=0%; East Asian, North=3.45%; East Asian, South=0%; South Asian=1.1%; European, North=61.67%; European, South=33.69% (PubMed=30894373).
CC   Derived from site: Metastatic; Pericardial effusion; UBERON=UBERON_0002409.
CC   Cell type: Club cell; CL=CL_0000158.
ST   Source(s): AddexBio=C0016019/4975; ATCC=HTB-174; CCRID=4201HUM-CCTCC00308; CLS=305219; Cosmic-CLP=908460; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D12S391: 19.3
ST   D13S317: 9
ST   D16S539: 9,13
ST   D18S51: 18,19
ST   D19S433: 14
ST   D21S11: 32.2
ST   D2S1338: 17,19
ST   D2S441: 14
ST   D3S1358: 18
ST   D5S818: 11,12
ST   D6S1043: 17
ST   D7S820: 10
ST   D8S1179: 8,14
ST   FGA: 24,25
ST   Penta D: 10,12
ST   Penta E: 12
ST   TH01: 9.3
ST   TPOX: 8,10
ST   vWA: 17
DI   NCIt; C5650; Lung papillary adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 48
//
 PubMed=7838528;
RA   Cheng N.C., Van Roy N., Chan A., Beitsma M., Westerveld A.,
RA   Speleman F., Versteeg R.;
RT   "Deletion mapping in neuroblastoma cell lines suggests two distinct
RT   tumor suppressor genes in the 1p35-36 region, only one of which is
RT   associated with N-myc amplification.";
RL   Oncogene 10:291-297(1995).
//
ayashi Y., Schlieve C.R., Ikeya M., Kim H.,
RA   Nguyen T.D., Sami S., Baba S., Barruet E., Nasu A., Asaka I.,
RA   Otsuka T., Yamanaka S., Conklin B.R., Toguchida J., Hsiao E.C.;
RT   "Induced pluripotent stem cells from patients with human
RT   fibrodysplasia ossificans progressiva show increased mineralization
RT   and cartilage formation.";
RL   Orphanet J. Rare Dis. 8:190.1-190.14(2013).
//
, Miranda C.L., Buhler D.R., Barnes D.W.;
RT   "Culture of cells from zebrafish (Brachydanio rerio) embryo and adult
RT   tissues.";
RL   Cell Biol. Toxicol. 8:43-61(1992).
//
 G.-H., Tabata H., Kuhara M., Kitahara I., Takashima Y.,
RA   Wada Y.;
RT   "Generation of chicken monoclonal antibodies against the a1, a2, and
RT   a3 subunit isoforms of vacuolar-type proton ATPase.";
RL   Hybridoma 30:199-203(2011).
//
mouse fibroblasts carrying human beta-2
RT   microglobulin.";
RL   Immunogenetics 22:1-8(1985).
//
and transcriptional upregulation of the
RT   sarco/endoplasmic reticulum Ca2+ transport ATPase in
RT   thapsigargin-resistant hamster smooth muscle cells.";
RL   Nucleic Acids Res. 26:4529-4537(1998).
//
C., Chen J.-Y.,
RA   Morelli E., Waszyk P., Kumar S., Deming D., Moret N., Rodriguez S.,
RA   Subramanian K., Rogava M., Cartwright A.N.R., Luoma A., Mei S.-L.,
RA   Brinker T.J., Miller D.M., Spektor A., Schadendorf D., Riggi N.,
RA   Wucherpfennig K.W., Sorger P.K., Izar B.;
RT   "Inhibition of haspin kinase promotes cell-intrinsic and extrinsic
RT   antitumor activity.";
RL   Cancer Res. 80:798-810(2020).
//
 for an increase in the resistant
RT   population following transformation.";
RL   Carcinogenesis 4:857-861(1983).
//
47:4068-4085(2019).
//
6-4;
RA   Kaiser-McCaw Hecht B., Epstein A.L., Berger C.S., Kaplan H.S.,
RA   Hecht F.;
RT   "Histiocytic lymphoma cell lines: immunologic and cytogenetic
RT   studies.";
RL   Cancer Genet. Cytogenet. 14:205-218(1985).
//
87; DOI=10.1038/nature09671; PMCID=PMC5024568;
RA   Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W.-M., Lim K.-H.,
RA   Kohlhammer H., Xu W.-H., Yang Y.-D., Zhao H., Shaffer A.L. 3rd,
RA   Romesser P.B., Wright G., Powell J.I., Rosenwald A.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D.,
RA   Chan W.-C., Staudt L.M.;
RT   "Oncogenically active MYD88 mutations in human lymphoma.";
RL   Nature 470:115-119(2011).
//
0.1038/nature05329; PMCID=PMC2669898;
RA   Redon R., Ishikawa S., Fitch K.R., Feuk L., Perry G.H., Andrews T.D.,
RA   Fiegler H., Shapero M.H., Carson A.R., Chen W.-W., Cho E.K., Dallaire S.,
RA   Freeman J.L., Gonzalez J.R., Gratacos M., Huang J., Kalaitzopoulos D.,
RA   Komura D., MacDonald J.R., Marshall C.R., Mei R., Montgomery L.,
RA   Nishimura K., Okamura K., Shen F., Somerville M.J., Tchinda J.,
RA   Valsesia A., Woodwark C., Yang F.-T., Zhang J.-J., Zerjal T., Zhang J.,
RA   Armengol L., Conrad D.F., Estivill X., Tyler-Smith C., Carter N.P.,
RA   Aburatani H., Lee C., Jones K.W., Scherer S.W., Hurles M.E.;
RT   "Global variation in copy number in the human genome.";
RL   Nature 444:444-454(2006).
//
azquez E.J., Weber K.S.,
RA   Robison R.A., O'Neill K.L.;
RT   "Non-small-cell lung cancer cell lines A549 and NCI-H460 express
RT   hypoxanthine guanine phosphoribosyltransferase on the plasma
RT   membrane.";
RL   Onco Targets Ther. 10:1921-1932(2017).
//
Cell Genet. 8:451-464(1982).
//
D4+ T-cell clone (PM1): failure
RT   to downregulate CD4 and to interfere with cell-line-tropic HIV-1.";
RL   J. Virol. 69:3712-3720(1995).
//
occuni P., Di Noto R., Del Vecchio L., Salvatore F., Rotoli B.;
RT   "Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+)
RT   and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+)
RT   lymphoma/leukemia.";
RL   Haematologica 85:496-501(2000).
//
E., Maiorana L., Vasta V., Pezzino F.M., Sunkara S., Wynne K.,
RA   Elia G., Marincola F.M., McCubrey J.A., Libra M., Travali S., Kane M.;
RT   "Characterization of human melanoma cell lines and melanocytes by
RT   proteome analysis.";
RL   Cell Cycle 10:2924-2936(2011).
//
col. 28:461-464(1991).
//
sner A., Musunuru K., Kathiresan S.,
RA   Daheron L., Zhu J., Gerszten R.E., Deo R.C., Vasan R.S.,
RA   O'Donnell C.J., Cowan C.A.;
RT   "Induced pluripotent stem cell differentiation enables functional
RT   validation of GWAS variants in metabolic disease.";
RL   Cell Stem Cell 20:547-557.e7(2017).
//
0/15384101.2017.1371880; PMCID=PMC5638364;
RA   Moraleva A., Magoulas C., Polzikov M.A., Hacot S., Mertani H.C.,
RA   Diaz J.-J., Zatsepina O.V.;
RT   "Involvement of the specific nucleolar protein SURF6 in regulation of
RT   proliferation and ribosome biogenesis in mouse NIH/3T3 fibroblasts.";
RL   Cell Cycle 16:1979-1991(2017).
//
hatic vessel endothelial hyaluronan receptor 1.";
RL   Cancer Sci. 109:3171-3182(2018).
//
ussell E., Johnson B., Buchhagen D.L., Bodner S.M., Phelps R.M.,
RA   Gazdar A.F., Minna J.D.;
RT   "High frequency of somatically acquired p53 mutations in small-cell
RT   lung cancer cell lines and tumors.";
RL   Oncogene 7:339-346(1992).
//
Med=9817906; DOI=10.1128/jcm.36.12.3718-3720.1998; PMCID=PMC105273;
RA   Schultz-Cherry S., Dybdahl-Sissoko N., McGregor M., Hinshaw V.S.;
RT   "Mink lung epithelial cells: unique cell line that supports influenza
RT   A and B virus replication.";
RL   J. Clin. Microbiol. 36:3718-3720(1998).
//
.,
RA   Osborne B.;
RT   "Characterization of a mutant T-cell hybridoma line with defects in
RT   the TCR-mediated apoptotic pathway.";
RL   Cell Death Differ. 6:36-47(1999).
//
omi M., Goto S.;
RT   "Correction to: Aurora B kinase as a therapeutic target in acute
RT   lymphoblastic leukemia.";
RL   Cancer Chemother. Pharmacol. 88:1055-1056(2021).
//